Company intelligence / Profile preview

Exeltis

Ownership: Private
Employees: ~4000
Development stage: Commercial

Overview

Exeltis has successfully commercialized several women’s health products globally. Its estrogen-free contraceptive Slynd underwent extensive clinical trials involving approximately 3,000 women across phases I–III before approval. The company also markets a range of prenatal vitamins and treatments for vaginal infections.

Therapeutic areas: Women's HealthNeurologyInfectious Diseases
Modalities: Small molecules (e.g., oral contraceptives like drospirenone)Nutritional supplements (e.g., prenatal vitamins)Medical devices
Industry: Biotech

Drug pipeline

8 assets

Gynomax

7 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Exeltis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exeltis.

Explore the full profile